Alligator Axes 70% of Staff Amid ‘Capital Constraints,’ Renews Pancreatic Cancer Focus

Alongside the layoffs, Alligator will also suspend work on all of its earlier-stage assets and devote its resources to lead candidate mitazalimab, being developed for the frontline treatment of metastatic pancreatic cancer.

Scroll to Top